Clorazepate

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Clorazepate

Examples of brand names: Tranxilium [DE]

ATC code: N05BA05

Main use (for orientation): Anxiety

Documented research summary

CBD cohort: clorazepate n=10 (2 adults/8 children), p=0.4423; no significant concentration signal. This does not establish equivalence or general safety. Additive sedation remains independently possible.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0059

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.4423.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=10.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[V2_LABEL_D0070] CLORAZEPATE DIPOTASSIUM TABLET [PD-RX PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: PD-RX PHARMACEUTICALS, INC.

Year: 2026

Source type: US SPL / DailyMed regulatory product labelling

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility